Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Gastrointestinal Cancer"
DOI: 10.1007/s12029-020-00375-2
Abstract: Background Telotristat ethyl is approved to treat carcinoid syndrome diarrhea in combination with somatostatin analogs. In TELESTAR and TELECAST phase III studies, patients with carcinoid syndrome received telotristat ethyl 250 or 500 mg 3 times per… read more here.
Keywords: frequency; telotristat ethyl; time; carcinoid syndrome ... See more keywords
Telotristat ethyl reverses myxomatous changes in mice mitral valves
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Cardiovascular Medicine"
DOI: 10.3389/fcvm.2022.945672
Abstract: Rationale Myxomatous mitral valve degeneration is a common pathological manifestation of mitral valve regurgitation, with or without valvular prolapse. In addition to similarities between naturally occurring and serotonergic valve degeneration, an increasing body of evidence… read more here.
Keywords: serotonin; degeneration; myxomatous changes; disease ... See more keywords